Randomisation and masking
Block randomisation was performed for each site via a centralised web app designed by MORU software engineers using RShiny, hosted on a MORU webserver. At enrolment, after obtaining fully informed consent and entering the patient details, the app provided the study drug allocation. The no study drug group comprised a minimum proportion of 20% of patients at all times, with uniform randomisation ratios applied across the active treatment groups (molnupiravir or ritonavir-boosted nirmatrelvir are reported here). Randomisation was done by the trial statistician. The laboratory team were masked to treatment allocation and the clinical investigators were masked to the virology results until the study group was terminated. Apart from the trial statistician (JAW), the clinical investigators were all masked to the quantitative PCR (qPCR) results.For 